About Us

Who We Are

Glyvantis Bio is a University College Dublin spin-out, based in Dublin, Ireland.

Our technology is set to change pharmaceutical antibody drug development.

We combine a highly accredited scientific founder with an expert team of drug developers and biotech entrepreneurs who are collectively advancing and commercializing the science.

Key Potential Benefits of Glyvantis Bio Technology

Consistent galactosylation of antibodies with improved clinical profile.

Eliminates product variability challenges and improves reproducibility in drug manufacturing.

Allows for the creation of new IP opportunities for existing antibodies coming off patent.

Allows for the creation of new drugs based on protein backbones of existing antibodies.

Allows development of antibodies that have failed development due to a narrow therapeutic window.